Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tecentriq (atezolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.